The Access to Medicine Foundation, in a Netherlands-based report, warns that the rush into GLP-1 weight-loss drugs such as Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro is pulling companies toward obesity markets and away from insulin. CEO Jay Iyer said 589 million adults have diabetes, 81% in low